二甲双胍联合炔雌醇环丙孕酮治疗多囊卵巢综合征不孕症的临床分析被引量：9

下载PDF

导出

摘要目的:分析二甲双胍联合炔雌醇环丙孕酮治疗多囊卵巢综合征不孕症的临床价值。方法:将在我院采用二甲双胍联合炔雌醇环丙孕酮治疗的56例多囊卵巢综合征不孕症患者纳入观察组,并按1∶1比例将56例采用单一二甲双胍或炔雌醇环丙孕酮治疗的多囊卵巢综合征不孕症患者纳入对照组,对比睾酮(T)、雌二醇(E_2)、卵泡刺激素(FSH)、黄体生成素(LH)等激素水平的变化情况,并统计排卵率、妊娠率、不良反应发生率。结果:治疗前,两组T、E_2、FSH、LH水平对比无显著差异(P>0.05),治疗后,观察组T、LH水平显著低于对照组,差异有统计学意义(P<0.05);两组E_2、FSH水平对比差异无统计学意义(P>0.05);同时,治疗期间,两组均未出现肝、肾等功能异常现象,无任何不良反应发生,观察组排卵率、妊娠率皆较对照组高,差异有统计学意义(P<0.05)。结论:二甲双胍联合炔雌醇环丙孕酮治疗多囊卵巢综合征不孕症对激素水平的改善作用更为显著,可有效提高排卵率,增加妊娠率。

作者李睿

机构地区孟州市人民医院妇产科

出处《北方药学》 2018年第5期61-61,共1页 Journal of North Pharmacy

关键词二甲双胍炔雌醇环丙孕酮多囊卵巢综合征不孕症

分类号 R711.75 [医药卫生—妇产科学]

引文网络
相关文献

参考文献3

1徐岚,熊煜.炔雌醇环丙孕酮联合二甲双胍对多囊卵巢综合征患者排卵的影响[J].中国药房,2016,27(24):3368-3370. 被引量：63
2郁琦.多囊卵巢综合征诊治标准专家共识[J].中国实用妇科与产科杂志,2007,23(6):474-474. 被引量：107
3张彩宇,陶爱群,莫有珍.二甲双胍与炔雌醇环丙孕酮片联用对多囊卵巢综合征患者相关激素分泌水平的影响[J].中国现代医学杂志,2016,26(9):85-88. 被引量：71

二级参考文献25

1DIAZ M, CHACON M R, LOPEZ-BERMEJO A, et al. Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue[J]. J Clin Endocrinol Metab, 2012, 97(10): 3630-3638.
2CINAR N, HARMANCI A, BAYRAKTAR M, et al. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome[J]. Clin Endocrinol, 2013, 78(3): 379-384.
3CHRISTAKOU C, KOLLIAS A, PIPERI C, et al. The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers[J]. Hormones, 2015, 13(4): 488-497.
4GLINTBORG D, MUMM H, ALTINOK M L, et al. Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome[J]. J Endocrinol Invest, 2014, 37(8): 757-764.
5GANIE M A, KHURANA M L, NISAR S, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study[J]. J Clin Endocrinol Metab, 2013, 98(9): 3599-3607.
6KAYA M G, CALAPKORUR B, KARACA Z, et al. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome[J]. Clin Endocrinol, 2012, 77(6): 885-892.
7GODE F, KARAGOZ C, POSACI C, et al. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate[J]. Arch Gynecol Obstet, 2011, 284(4): 923-929.
8WILLIAMS R M, ONG K K, DUNGER D B. Polycystic ovarian syndrome during puberty and adolescence[J]. Mol Cell Endocrinol, 2013, 373(1/2): 61-67.
9Geisthovel F. A comment on the European Society of HumanReproduction and Embryology/American Society forReproductive Medicine consensus of the polycystic ovariansyndrome[J]. Reprod Biomed Online,2003,7(6):602.
10Cagnaeci A,Paoletti AM,Renzi A. Glucose metabolismand insulin resistance in women with polycystic ovarysyndrome during therapy with oral contraceptives containingcyproterone acetate or desogestrel [J]. J Clin EndocfinolMetab,2003,88(8):3 621.